Deletion of interleukin‐6 in mice with the dominant negative form of transforming growth factor β receptor II improves colitis but exacerbates autoimmune cholangitis

The role of interleukin‐6 (IL‐6) in autoimmunity attracts attention because of the clinical usage of monoclonal antibodies to IL‐6 receptor (IL‐6R), designed to block IL‐6 pathways. In autoimmune liver disease, activation of the hepatocyte IL‐6/STAT3 (signal transducer and activator of transcription 3) pathway is associated with modulating pathology in acute liver failure, in liver regeneration, and in the murine model of concanavalin A–induced liver inflammation. We have reported that mice expressing a dominant negative form of transforming growth factor β receptor II (dnTGFβRII) under control of the CD4 promoter develop both colitis and autoimmune cholangitis with elevated serum levels of IL‐6. Based on this observation, we generated IL‐6–deficient mice on a dnTGF‐βRII background (dnTGFβRII IL‐6−/−) and examined for the presence of antimitochondrial antibodies, levels of cytokines, histopathology, and immunohistochemistry of liver and colon tissues. As expected, based on reports of the use of anti–IL‐6R in inflammatory bowel disease, dnTGFβRII IL‐6−/− mice manifest a dramatic improvement in their inflammatory bowel disease, including reduced diarrhea and significant reduction in intestinal lymphocytic infiltrates. Importantly, however, autoimmune cholangitis in dnTGFβRII IL‐6−/− mice was significantly exacerbated, including elevated inflammatory cytokines, increased numbers of activated T cells, and worsening hepatic pathology. Conclusion: The data from these observations emphasize that there are distinct mechanisms involved in inducing pathology in inflammatory bowel disease compared to autoimmune cholangitis. These data also suggest that patients with inflammatory bowel disease may not be the best candidates for treatment with anti–IL‐6R if they have accompanying autoimmune liver disease and emphasize caution for therapeutic use of anti–IL‐6R antibody. HEPATOLOGY 2010

[1]  J. Scheller,et al.  Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. , 2010, Journal of autoimmunity.

[2]  I. Mackay,et al.  B‐cell depletion with anti‐CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor‐β receptor II dominant negative mice , 2009, Hepatology.

[3]  Y. Shoenfeld,et al.  Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. , 2009, Journal of autoimmunity.

[4]  I. Mackay,et al.  Deletion of interleukin‐12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor β receptor type II mice , 2009, Hepatology.

[5]  F. Cicuttini,et al.  Targeting IL-6 in the treatment of inflammatory and autoimmune diseases , 2009, Expert opinion on investigational drugs.

[6]  Ana Lleo,et al.  Primary biliary cirrhosis is associated with altered hepatic microRNA expression. , 2009, Journal of autoimmunity.

[7]  I. Mackay,et al.  B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. , 2009, Gastroenterology.

[8]  I. Mackay,et al.  Apotopes and the biliary specificity of primary biliary cirrhosis , 2009, Hepatology.

[9]  K. Tsuneyama,et al.  Hepatic IL-17 responses in human and murine primary biliary cirrhosis. , 2009, Journal of autoimmunity.

[10]  S. Glaser,et al.  Cholangiocyte proliferation and liver fibrosis , 2009, Expert Reviews in Molecular Medicine.

[11]  K. Tsuneyama,et al.  Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis , 2009, Hepatology.

[12]  I. Mackay,et al.  Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin‐2Rα−/− mice , 2009, Hepatology.

[13]  M. Rincón,et al.  The effects of IL-6 on CD4 T cell responses. , 2009, Clinical immunology.

[14]  Jia-hong Dong,et al.  Activation of Interleukin-6/STAT3 in Rat Cholangiocyte Proliferation Induced by Lipopolysaccharide , 2009, Digestive Diseases and Sciences.

[15]  I. Mackay,et al.  CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. , 2008, Journal of autoimmunity.

[16]  Y. Nakanuma,et al.  Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/Cip1 in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. , 2008, Journal of autoimmunity.

[17]  M. Neurath,et al.  The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. , 2008, The Journal of clinical investigation.

[18]  I. Mackay,et al.  Adoptive transfer of CD8+ T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice , 2008, Hepatology.

[19]  C. Sautès-Fridman,et al.  Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. , 2008, Journal of autoimmunity.

[20]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[21]  J. Scheller,et al.  Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. , 2008, Blood.

[22]  T. Kishimoto,et al.  Humanized antihuman IL-6 receptor antibody, tocilizumab. , 2008, Handbook of experimental pharmacology.

[23]  M. Neurath,et al.  Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. , 2007, Inflammatory bowel diseases.

[24]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[25]  S. Glaser,et al.  Taurocholic Acid Feeding Prevents Tumor Necrosis Factor-α–Induced Damage of Cholangiocytes by a PI3K–Mediated Pathway , 2007, Experimental biology and medicine.

[26]  J. Scheller,et al.  The IL-6/sIL-6R complex as a novel target for therapeutic approaches , 2007, Expert opinion on therapeutic targets.

[27]  S. Glaser,et al.  Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. , 2007, Gastroenterology.

[28]  A. Leung,et al.  Primary Biliary Cirrhosis , 2007 .

[29]  T. Kishimoto,et al.  Interleukin 6: from bench to bedside , 2006, Nature Clinical Practice Rheumatology.

[30]  I. Mackay,et al.  IL‐2 receptor α−/− mice and the development of primary biliary cirrhosis , 2006 .

[31]  I. Mackay,et al.  Anti-Mitochondrial Antibodies and Primary Biliary Cirrhosis in TGF-β Receptor II Dominant-Negative Mice1 , 2006, The Journal of Immunology.

[32]  I. Mackay,et al.  NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis , 2006, The Journal of experimental medicine.

[33]  I. Mackay,et al.  IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. , 2006, Hepatology.

[34]  M. Neurath,et al.  Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer , 2005, Clinical reviews in allergy & immunology.

[35]  I. McKillop,et al.  Interleukin‐6 inhibits cell proliferation in a rat model of hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[36]  K. Tsuneyama,et al.  Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital , 2004, Modern Pathology.

[37]  永野 拓也.  Cytokine Profile in the Liver of Primary Biliary Cirrhosis , 2000 .

[38]  J. Lunz,et al.  The effect of interleukin-6 (IL-6)/gp130 signalling on biliary epithelial cell growth, in vitro. , 2000, Cytokine.

[39]  J. Lunz,et al.  The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. , 2000, The American journal of pathology.

[40]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[41]  M. Manns,et al.  The tumor necrosis factor-α promoter correlates with progression of primary biliary cirrhosis , 1999 .

[42]  G. Gores,et al.  Lipopolysaccharide induces cholangiocyte proliferation via an interleukin‐6–mediated activation of p44/p42 mitogen‐activated protein kinase , 1999, Hepatology.

[43]  M. Manns,et al.  The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. , 1999, Journal of hepatology.

[44]  G. Michalopoulos,et al.  Interleukin‐6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type i ductular reaction in mice: Interactions between the periductal inflammatory and stromal cells and the biliary epithelium , 1998, Hepatology.

[45]  V. Poli,et al.  Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus , 1998, The Journal of experimental medicine.

[46]  I. Rensink,et al.  Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study , 1998, British journal of haematology.

[47]  T. Hirano.  Interleukin 6 and its receptor: ten years later. , 1998, International reviews of immunology.

[48]  E. Dickson,et al.  Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies , 1996, Hepatology.

[49]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[50]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[51]  K. Tanikawa,et al.  Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. , 1995, Gut.

[52]  G. Fantuzzi,et al.  Defective inflammatory response in interleukin 6-deficient mice , 1994, The Journal of experimental medicine.

[53]  G. Michalopoulos,et al.  Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: Interleukin‐6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro , 1994, Hepatology.

[54]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[55]  F. Rocca,et al.  Familial aggregation of inflammatory bowel disease in northern Italy: a multicenter study. The Gruppo di Studio per le Malattie Infiammatorie Intestinali (IBD Study Group). , 1992, Gastroenterology.

[56]  S. Thorgeirsson,et al.  Effects of interleukin-6 on the growth of normal and transformed rat liver cells in culture. , 1989, Growth factors.

[57]  A Muraguchi,et al.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells , 1988, The Journal of experimental medicine.

[58]  I. Mackay,et al.  Molecular cloning of the liver-specific rat F antigen. , 1987, Journal of immunology.

[59]  M. Kaplan,et al.  Primary biliary cirrhosis. , 1987, The New England journal of medicine.

[60]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.